目的分析胎儿超声心动图联合母体血清分泌型卷曲相关蛋白5(secreted frizzled-related protein 5,SFRP5)、同型半胱氨酸(homocysteine,Hcy)浓度对先天性心脏病(先心病)胎儿的诊断效能。方法选取2018年7月至2022年2月在十堰市妇幼保健院...目的分析胎儿超声心动图联合母体血清分泌型卷曲相关蛋白5(secreted frizzled-related protein 5,SFRP5)、同型半胱氨酸(homocysteine,Hcy)浓度对先天性心脏病(先心病)胎儿的诊断效能。方法选取2018年7月至2022年2月在十堰市妇幼保健院进行孕中期产前检查的孕妇2756例为研究对象,根据妊娠结局将孕妇分为先心病组(n=110),正常组(n=2646)。孕中期均行胎儿超声心动图检查。酶联免疫吸附法试验(enzymelinked immunosorbent assay,ELISA)检测母体血清SFRP5浓度,全自动生化分析仪检测Hcy浓度。Pearson法分析先心病组母体血清SFRP5浓度与Hcy浓度的相关性。以妊娠结局为“金标准”,分析胎儿超声心动图、母体血清SFRP5、Hcy浓度及三者联合对先心病胎儿的诊断效能。结果先心病组母体血清SFRP5浓度明显低于正常组(P<0.05),Hcy浓度明显高于正常组(P<0.05),两者浓度呈负相关(r=-0.575,P<0.05)。胎儿超声心动图、母体血清SFRP5、Hcy浓度诊断先天性心脏病胎儿的灵敏度分别为63.64%、64.55%、65.45%,特异度分别为81.52%、81.07%、80.35%,准确度分别为80.81%、80.41%、79.75%。胎儿超声心动图、母体血清SFRP5、Hcy浓度联合诊断先心病胎儿的灵敏度、准确度分别为96.36%、80.91%,均高于三者单独检测,且三者联合诊断的灵敏度显著高于三者单独诊断(P<0.05)。结论胎儿超声心动图联合母体血清SFRP5、Hcy浓度对先心病胎儿具有较高的诊断价值,三者联合诊断可提高灵敏度。展开更多
目的分析孕中期妊娠期糖尿病(GDM)患者血清α清蛋白(Afamin)和分泌型卷曲相关蛋白5(SFRP5)水平及临床价值。方法选取2019年8月至2021年8月河北省秦皇岛市海港医院120例定期产检并分娩的孕妇为研究对象,其中GDM孕妇50例为GDM组,非GDM孕...目的分析孕中期妊娠期糖尿病(GDM)患者血清α清蛋白(Afamin)和分泌型卷曲相关蛋白5(SFRP5)水平及临床价值。方法选取2019年8月至2021年8月河北省秦皇岛市海港医院120例定期产检并分娩的孕妇为研究对象,其中GDM孕妇50例为GDM组,非GDM孕妇70例为对照组。采用酶联免疫吸附试验(ELISA)检测两组血清Afamin和SFRP5水平;采用口服葡萄糖耐量试验(OGTT)检测OGTT 1 h血糖(1 h PG)、OGTT 2 h血糖(2 h PG);检测空腹血糖(FPG)、糖化血红蛋白(HbA1c)及空腹胰岛素(FINS)水平;分析Afamin、SFRP5与糖代谢指标之间的相关性;采用受试者工作特征(ROC)曲线评估Afamin、SFRP5单独及联合检测对GDM的诊断价值;分析不同Afamin、SFRP5水平孕妇不良妊娠结局发生情况。结果GDM组FPG、1 h PG、2 h PG、HbA1c和FINS水平明显高于对照组,差异有统计学意义(P<0.05);GDM组Afamin水平明显高于对照组,SFRP5水平明显低于对照组,差异有统计学意义(P<0.05);Afamin水平与FPG、1 h PG、2 h PG、HbA1c和FINS水平呈正相关(P<0.05);SFRP5水平与FPG、1 h PG、2 h PG、HbA1c和FINS水平呈负相关(P<0.05);ROC曲线分析结果显示,血清Afamin和SFRP5单独及联合检测诊断GDM的曲线下面积(AUC)分别为0.747、0.642、0.872,且联合检测的灵敏度为89.3%,特异度为77.9%,联合检测的AUC明显大于单独检测的AUC,差异有统计学意义(P<0.05)。以所有孕妇的Afamin、SFRP5水平均值为界,分为高Afamin组、低Afamin组,以及高SFRP5组、低SFRP5组,高Afamin组母婴不良妊娠结局发生率高于低Af amin组,低SFRP5组母婴不良妊娠结局发生率高于高SFRP5组,差异有统计学意义(P<0.05)。结论Afamin和SFRP5作为诊断GDM的生物标志物具有良好的效能,在临床上可以预测GDM的发展趋势和不良妊娠结局的风险。展开更多
Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin res...Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.展开更多
目的分析血清分泌型卷曲蛋白5(secreted frizzled-related protein 5,SFRP5)水平与原发性高血压早期肾损害的相关性。方法选取2017年1-12月就诊于河北医科大学第二医院首次诊断为原发性高血压患者88例和同时期健康体检者32例(A组)。根...目的分析血清分泌型卷曲蛋白5(secreted frizzled-related protein 5,SFRP5)水平与原发性高血压早期肾损害的相关性。方法选取2017年1-12月就诊于河北医科大学第二医院首次诊断为原发性高血压患者88例和同时期健康体检者32例(A组)。根据尿白蛋白/肌酐比值(urine albumin creatine ratio,UACR)对88例原发性高血压患者进行分组,无早期肾损害者(UACR<30mg/g)41例(B组),存在早期肾损害(30mg/g≤UACR≤300mg/g)者47例(C组)。比较3组SFRP5、胱抑素C(cystatin C,Cys-C)、尿素氮、肌酐水平。结果(1)C组SFRP5水平低于A组、B组(P<0.01),B组SFRP5水平低于A组(P<0.05)。(2)C组Cys-C水平高于A组、B组(P<0.01)。(3)SFRP5与UACR、Cys-C呈负相关(r=-0.839,P<0.01;r=-0.378,P<0.05)。Cys-C与UACR呈正相关(r=0.625,P<0.01)。(4)SFRP5是高血压肾损害的独立保护因子(β=-0.036,P<0.01),Cys-C是高血压肾损害的独立危险因素(β=0.288,P<0.01)。结论SFRP5是高血压患者早期肾损害的保护性因子,有可能成为高血压患者早期肾损害预测和治疗的新靶点之一,为临床用药和评价药物疗效提供新的方向。展开更多
文摘目的分析孕中期妊娠期糖尿病(GDM)患者血清α清蛋白(Afamin)和分泌型卷曲相关蛋白5(SFRP5)水平及临床价值。方法选取2019年8月至2021年8月河北省秦皇岛市海港医院120例定期产检并分娩的孕妇为研究对象,其中GDM孕妇50例为GDM组,非GDM孕妇70例为对照组。采用酶联免疫吸附试验(ELISA)检测两组血清Afamin和SFRP5水平;采用口服葡萄糖耐量试验(OGTT)检测OGTT 1 h血糖(1 h PG)、OGTT 2 h血糖(2 h PG);检测空腹血糖(FPG)、糖化血红蛋白(HbA1c)及空腹胰岛素(FINS)水平;分析Afamin、SFRP5与糖代谢指标之间的相关性;采用受试者工作特征(ROC)曲线评估Afamin、SFRP5单独及联合检测对GDM的诊断价值;分析不同Afamin、SFRP5水平孕妇不良妊娠结局发生情况。结果GDM组FPG、1 h PG、2 h PG、HbA1c和FINS水平明显高于对照组,差异有统计学意义(P<0.05);GDM组Afamin水平明显高于对照组,SFRP5水平明显低于对照组,差异有统计学意义(P<0.05);Afamin水平与FPG、1 h PG、2 h PG、HbA1c和FINS水平呈正相关(P<0.05);SFRP5水平与FPG、1 h PG、2 h PG、HbA1c和FINS水平呈负相关(P<0.05);ROC曲线分析结果显示,血清Afamin和SFRP5单独及联合检测诊断GDM的曲线下面积(AUC)分别为0.747、0.642、0.872,且联合检测的灵敏度为89.3%,特异度为77.9%,联合检测的AUC明显大于单独检测的AUC,差异有统计学意义(P<0.05)。以所有孕妇的Afamin、SFRP5水平均值为界,分为高Afamin组、低Afamin组,以及高SFRP5组、低SFRP5组,高Afamin组母婴不良妊娠结局发生率高于低Af amin组,低SFRP5组母婴不良妊娠结局发生率高于高SFRP5组,差异有统计学意义(P<0.05)。结论Afamin和SFRP5作为诊断GDM的生物标志物具有良好的效能,在临床上可以预测GDM的发展趋势和不良妊娠结局的风险。
文摘Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea–hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m2. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=?0.472 and P=0.003; r=?0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However,no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.
文摘目的分析血清分泌型卷曲蛋白5(secreted frizzled-related protein 5,SFRP5)水平与原发性高血压早期肾损害的相关性。方法选取2017年1-12月就诊于河北医科大学第二医院首次诊断为原发性高血压患者88例和同时期健康体检者32例(A组)。根据尿白蛋白/肌酐比值(urine albumin creatine ratio,UACR)对88例原发性高血压患者进行分组,无早期肾损害者(UACR<30mg/g)41例(B组),存在早期肾损害(30mg/g≤UACR≤300mg/g)者47例(C组)。比较3组SFRP5、胱抑素C(cystatin C,Cys-C)、尿素氮、肌酐水平。结果(1)C组SFRP5水平低于A组、B组(P<0.01),B组SFRP5水平低于A组(P<0.05)。(2)C组Cys-C水平高于A组、B组(P<0.01)。(3)SFRP5与UACR、Cys-C呈负相关(r=-0.839,P<0.01;r=-0.378,P<0.05)。Cys-C与UACR呈正相关(r=0.625,P<0.01)。(4)SFRP5是高血压肾损害的独立保护因子(β=-0.036,P<0.01),Cys-C是高血压肾损害的独立危险因素(β=0.288,P<0.01)。结论SFRP5是高血压患者早期肾损害的保护性因子,有可能成为高血压患者早期肾损害预测和治疗的新靶点之一,为临床用药和评价药物疗效提供新的方向。